



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

# ANNUAL ACCOUNTS

for



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

Org. no.  
802428-5986

# THE FINANCIAL YEAR 2019

**IFPA Secretariat**  
Gustavslundsvägen 143  
167 51 Bromma  
SWEDEN

[www.ifpa-pso.com](http://www.ifpa-pso.com)  
[info@ifpa-pso.com](mailto:info@ifpa-pso.com)  
[@psoriasisIFPA](https://twitter.com/psoriasisIFPA)





## Director's Declaration 2019 (Annual Report)

### Purpose

The purposes, for which the Federation is formed, are to advance efforts to lessen the suffering of people with psoriasis and psoriatic arthritis and to improve methods of treatment and research for finding the ultimate cause and cure of the disease. In order to realize its purposes, the Federation shall:

- a) Represent the interests of its member associations in international forums such as the World Health Organization, the World Congress of Dermatology and international psoriasis symposia. IFPA shall also in close cooperation with other relevant international organizations organize international conferences, symposia and other events related to psoriasis and psoriatic arthritis, notably the annual global World Psoriasis Day campaign.
- b) Provide advice and consultation on the problems associated with psoriasis and psoriatic arthritis to member organizations or other communities and organizations worldwide.
- c) Provide the basis for closer liaison and the free exchange of information among psoriasis organizations and related organizations worldwide.
- d) Encourage and assist the establishment of new national organizations of people with psoriasis and psoriatic arthritis.
- e) Contribute to the improvement of the quality of health and social life of people suffering from psoriasis and psoriatic arthritis.
- f) The Federation shall not supersede or contravene the autonomy of national or other member organizations.

### Vision

Achieve a world without suffering from psoriasis and psoriatic arthritis.

### Mission

Be the global psoriasis advocacy association, with a focus on empowering our members, improving living conditions for psoriasis patients, raising awareness and cooperating with fellow stakeholders.





## Goals

IFPA's goals as an organization are to:

1. Empower national psoriasis organizations by uniting them, strengthening their work and acting as their global voice.
2. Improve patients' living conditions by advocating for correct diagnosis, universal access to treatment and less discrimination and stigmatization.
3. Raise psoriasis awareness through education, information and highlighting research results.
4. Cooperate with relevant psoriasis stakeholders, including medical and pharmaceutical actors.

## Governance

IFPA is governed by the General Assembly (GA) of its Full Members. The meeting of the General Assembly is held every three years, which during 2019 was held on July 5th in Barcelona, Spain, followed on site by a Members Meeting on July 6th-7th.

In furtherance of the objectives of the Federation, the IFPA Board shall implement IFPA policies and management between official General Assembly meetings. The IFPA Board may also call an Extraordinary General Assembly meeting, either as a physical meeting or by postal/online vote, should any urgent amendments to or clarifications of the IFPA Constitution or Bylaws be deemed necessary.

In 2019 the IFPA Board had seven Board meetings, of which five physical and two telemeetings.

## IFPA Secretariat

The IFPA Secretariat was further expanded in 2019, with a Project Developer position added in January (with focus on World Psoriasis Day coordination, sponsor projects and internal systems development) and a new Scientific Officer joining the team in October. The previous Scientific Officer began study leave in January working 25% until summer and 100% during the summer months, and will continue intermittently during summer months only focused on preparations for the next IFPA World Psoriasis and Psoriatic Arthritis Conference, supporting as Scientific Coordinator.

By end of year, the IFPA Secretariat consisted of the Executive Director, Scientific Officer, Communications Manager, Program Officer – Advocacy and Policy, Program Officer – Capacity Development, and Project Developer, in addition to the part-of-year





Scientific Coordinator. The Manager Administration and Events position remained vacant during most of the year, with a tentative hire occurring during the second quarter and a final hire occurring in the last quarter, to join in January 2020. By end of year, the number of available full time staff positions at the Secretariat had increased further to 7,25 (including the 25% recurring Scientific Coordinator summer function).

## Key organizational developments for IFPA in 2019

- A more connected strategic approach for IFPA was introduced with the intent to more closely connect IFPA on global, regional and national levels for increased synergies, information sharing and impact in advocacy, communications, knowledge sharing and capacity development.
- A new multi-year approach was introduced for the Federation's key activities, connecting the World Psoriasis Day campaign as a three-year journey under the annual themes CONNECTED, INFORMED and UNITED, connecting to the upcoming IFPA World Psoriasis and Psoriatic Arthritis Conference in 2021.
- Following dialogue at the IFPA Members Meeting in July, the Board decided to adopt a regional members meeting methodology for each third year (beginning 2020) on trial basis as an alternative to each year's global members meeting, in order to follow up on regional development potential.
- IFPA's sponsorship support was substantially expanded in 2019 both due to new sponsors joining IFPA and expanded collaborations with existing sponsors.
- IFPA's collaboration with external partners was expanded upon.
- Board and Secretariat work systems and methodologies were further developed during the year, as part of the internal WISE program (Workplace Improvement and Systems Enhancement), including digitalization processes and further development of virtual meeting and work formats such as Microsoft Teams.

## Main IFPA activities in 2019

- IFPA General Assembly and Members Meeting
- IFPA Advocacy project and the Global Psoriasis Coalition
- Participation in the 72<sup>nd</sup> World Health Assembly and the United Nations High-Level Meeting on Universal Health Coverage in connection with the UNGA
- An IFPA / Global Psoriasis Coalition side event in connection with the UN HLM, in collaboration with the NCD Alliance
- Participation in other key events such as AAD, the World Congress of Dermatology, EADV, and others
- An expanded World Psoriasis Day campaign 2019 under the theme Let's Get CONNECTED, also the overarching theme for IFPA's efforts during the year





INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

- Launch of the Global Psoriasis Atlas (in collaboration with the GPA team and between the founding partners – IFPA, ILDS and IPC)
- Capacity building efforts for and with IFPA members, including a social media knowledge and capacity building project
- Introduction of a Psoriatic Disease Response Index as a collaborative project with IFPA sponsors (project continued in 2020)
- Participation in a global information campaign about non-communicable diseases, with psoriasis highlighted in a BBC production in collaboration with the NCD Alliance

## Advocacy and policy

IFPA's advocacy work in 2019 was mainly focused around development and deliverables of the Global Psoriasis Coalition (a key program of IFPA), advocacy in connection with international health policy meetings and relations with IFPA members around advocacy-related themes.

The Global Psoriasis Coalition, in collaboration with IFPA and the NCD Alliance, organized a side-event in connection with the United Nations High-Level Meeting on Universal Health Coverage. The side-event featured a panel discussion where panelists explored ways to optimize the health workforce to address shortages and provide adequate and person-centered care for non-communicable diseases. IFPA presented psoriasis as a test-case for universal health coverage, as psoriasis requires lifetime care optimally provided by a diverse team of healthcare providers including specialists as well as primary healthcare practitioners.

The Global Psoriasis Coalition launched a white paper on psoriasis and primary care entitled "Beyond gatekeeping: effective primary care support in the management of psoriasis and psoriatic arthritis", launched during the side-event alongside the United Nations High-level Meeting. The white paper details practical recommendations for improving primary care support systems for people living with psoriasis and psoriatic arthritis, and case studies on existing innovative models to improve psoriasis care.

Three in-person meetings were organized for Global Psoriasis Coalition members to discuss current themes as well as future actions of the Coalition. During the meetings. Ample space was given to the process that will shape the Psoriatic Disease Response Index, planned as a key deliverable of the Global Psoriasis Coalition for 2020.

A social media toolkit on psoriatic arthritis was distributed to Coalition members to raise awareness on psoriatic arthritis during Psoriatic Arthritis Awareness Month (May).

IFPA focused its advocacy activities around the 2019 theme of universal health coverage. As mentioned in the 2016 WHO Global report on Psoriasis, "meeting the global commitments to provide universal health coverage would have a significant





impact on improving the lives of people, especially those with chronic conditions such as psoriasis". IFPA representatives participated in the annual World Health Assembly (Geneva) and at the United Nations High-Level Meeting on Universal Health Coverage (New York). Learning points from these policy meetings were shared with the IFPA membership and used to produce a toolkit on universal health coverage tailored to the needs of psoriasis advocates.

The Global Psoriasis Coalition in 2019 expanded notably. IFPA would like to acknowledge and thank our supporters (listed in the "Corporate partners" section below) for making the important work of the Coalition possible. Multiple civil society partners joined the Coalition as members: The NCD Alliance, the Global Health Council, the International Alliance of Patient Organizations, and Global Skin (IADPO).

Overall, the Coalition grew decisively in size and scale of activities during 2019, and IFPA worked extensively on development and expansion. The High Lantern Group continued as consultants for IFPA for the Coalition during 2019, powering GPC activities.

More information about the Global Psoriasis Coalition is available on [www.globalpsoriasiscoalition.com](http://www.globalpsoriasiscoalition.com) and @psocoalition on Twitter.

## Science

IFPA's scientific work in 2019 was mainly focused on the Global Psoriasis Atlas to become a leading epidemiological resource mapping the global burden of psoriasis to fulfil the WHO report research needs. More information regarding this and preparations ahead of the 6<sup>th</sup> IFPA World Psoriasis and Psoriatic Arthritis Conference are available in separate paragraphs in this document. In addition, IFPA was well represented in leading dermatology and arthritis focused conferences (the American Academy of Dermatology in Washington, D.C., the World Congress of Dermatology in Milan, and the European Academy of Dermatology and Venereology conference in Madrid. IFPA was also represented at the EULAR conference in Madrid.

IFPA additionally published a position paper on biosimilars during the year, and provided input for the development of European Centre for Guidelines Development psoriasis guideline updates in Europe. IFPA also worked extensively together with corporate partners and IFPA members on a number of research projects and surveys.





## IFPA-arranged activities, external meetings and conference participations

IFPA was represented at numerous meetings, summits and conferences as relevant to IFPA's mission and where of importance for IFPA to be represented, to participate and to build relationships. Highlights include:

- Prince Mahidol Award Conference in Bangkok, January
- AAD, Washington, D.C., March
- Beyond 5x5 NCDs network meeting, Geneva, April
- Associations World Congress, Gothenburg, April
- SPIN, Paris, April
- United Nations Multi-Stakeholder Meeting, New York, April
- 72<sup>nd</sup> World Health Assembly, Geneva, May
- World Congress of Dermatology and the Global Skin Conference, Milan, June
- EULAR, Madrid, June
- Asian Patient Innovation Summit, Global City (Philippines), June
- United Nations High-Level Meeting on UHC, New York, September
- EADV, Madrid, October
- IAPO Asia-Pacific Patients Congress, November
- Site visits in connection with other travel to IFPA members in Sweden, Vietnam, United States, Finland, Denmark, Spain, and France

## IFPA General Assembly and Members Meeting

The IFPA 2019 General Assembly was arranged in Barcelona on July 5<sup>th</sup>, preceded by synergized regional meetings for IFPA members the same morning and followed by member meetings for IFPA members and with IFPA partners and sponsors on July 6<sup>th</sup> and 7<sup>th</sup>. The meetings were also followed by separate meetings with IFPA sponsors and partners, as well as a meeting for the Global Psoriasis Coalition.

The General Assembly elected and welcomed the new IFPA Board; Dr. Hoseah Waweru (President), Ingvar Ágúst Ingvarsson (Vice President), Leticia Lopez (Secretary), Josef de Guzman (Treasurer), Kathleen Gallant (Member-at-Large), Silvia Fernandez Barrio and David Trigos (substitutes), with thanks to the previous Board for their engaged efforts during their tenure.

The Members Meeting, which gathered over 90 participants from IFPA member associations and IFPA partners from different sectors. was utilized both as networking and synergy-building opportunities for the expanding IFPA network, and as a key moment to get CONNECTED and build momentum ahead of World Psoriasis Day 2019. IFPA members showcased national activities from around the world at a members reception where IFPA partners were also invited. Workshops and discussion sessions were organized in order to jointly build plans for IFPA's further development and





expansion, key speakers provided important updates and knowledge, and a Social Media Smart Bar and lectures provided expert knowledge and advice regarding social media utilization in the WPD campaign. The Meet the Sponsors section allowed for regional conversations between IFPA members and supporters.

We thank everyone for bringing so much energy and synergy to these days, making these meetings a key moment ahead of IFPA's further development and expansion.

## Members

By end of 2019, IFPA had 62 regional, national and associate members. IFPA welcomed several new members in 2019:

- *Asociación de Psoriasis y Arthritis Psoriásica - Perú (APAPSO Perú)* joined as a Full Member of IFPA.
- *Psoriasis Awareness Club Bangladesh* joined as an Associated Member of IFPA.
- *Canadian Psoriasis Network / Réseau Canadien du Psoriasis* joined as an Associated Member of IFPA.
- *Associazione Amici Della "Fondazione Natalino Corazza Onlus"* (Italy) joined as an Associated Member of IFPA.

## Capacity development

Through IFPA's new Capacity Development Program, a number of initiatives were organized for IFPA members in order to strengthen IFPA as a federation:

- A new webinar series with monthly webinars was launched. The webinar series, open for IFPA Members only, covered topics such as World Psoriasis Day, updates on IFPA's advocacy efforts and an introduction to the Global Psoriasis Atlas. During the year, 17 webinars were held with a total of 146 attendees.
- As noted in other sections, a particular social media capacity building project was organized in connection with the Members Meeting and WPD campaign.
- A member survey was conducted in April collecting extensive information from IFPA members around the world.
- IFPA introduced working groups as a new working format making it possible for individuals from all levels of the federation to come together and work jointly on specified projects. These groups were particularly active in capacity development projects and as part of the World Psoriasis Day campaign.
- Direct coordination meetings and site visits were organized by IFPA with national member associations in-country as listed in an earlier section.
- IFPA coordinated with regional member associations regularly during the year
- Regional meetings were introduced as a complementary member meeting concept, for implementation in 2020.





## Memberships in other organizations

IFPA renewed the collaboration with the NCD Alliance, the International Alliance of Patients' Organizations (IAPO) and the Global Health Council, established in previous years. Moreover, IFPA began collaborating with the International Alliance of Dermatology Patient Organizations (IADPO/Global Skin), with reciprocal associated/affiliate membership, and became a member of the Civil Society Engagement Mechanism for UHC (CSEM). IFPA is now also part of a network of organizations (led by the NCD Alliance) representing people living with non-communicable diseases unrepresented in the "5x5" WHO NCD framework.

## World Psoriasis Day 2019

The World Psoriasis Day theme for 2019 was Let's Get CONNECTED, the first year in a three-year effort to highlight the needs of people living with psoriasis and psoriatic arthritis and build synergy with IFPA's network, partners and stakeholders in the field. The logical chain is CONNECTED (2019), INFORMED (2020), and UNITED (2021). World Psoriasis Day 2019 was celebrated by over 60 patient organizations worldwide and many other stakeholders, and raised awareness for psoriasis and psoriatic arthritis globally.

The Let's Get CONNECTED theme highlighted how psoriasis and psoriatic is a connected disease through co-morbidities, while also emphasizing the need for patients to become connected to supportive communities such as patient organizations, for organizations and sectors to connect in joint efforts for synergies and impact, for patients to become more connected to quality healthcare and research processes, and specifically for IFPA to become more CONNECTED as an organization on all levels – something which became a focused methodology during the year.

IFPA developed a more extensive toolkit and work materials for the 2019 campaign than previous years. The Members Meeting in Barcelona in July was also utilized as a moment to get connected, for IFPA members, sponsors and partners, and set the stage ahead of an active WPD campaign.

The 2019 World Psoriasis Day campaign was widely perceived as highly successful and engaging, with increased social media engagement and connections, strengthened by a particular social media capacity building project for IFPA member organizations providing expert coaching, toolkits and information in order to further expand on IFPA's synergized social media messaging and communications in connection with the 2019 WPD campaign.





Some examples of activities by IFPA member associations include:

- In Italy, Associazione Amici Della Fondazione Natalino Corazza Onlus organized major photographic installations and flashmobs across five cities in the country.
- In Japan, the Inspire Japan WPD campaign created an engaging psoriasis-themed song with corresponding video production which was widely shared on social media.
- In Peru, APAPSO Perú developed a campaign named #ConoceLaPsoriasis (know psoriasis) to raise public awareness, showcasing graphics by Peruvian illustrators and designers, which were distributed through social media.
- The South African Psoriasis Association organized a patient meeting and a day of activities including talks on dermatology, rheumatology, and management of psoriasis.

Further information is available in the 2019 World Psoriasis Day Report.

The Let's Get Connected campaign was listed as one of the finalists in the International and European Association Awards, in the category Best Social Media Campaign.

## The Global Psoriasis Atlas

IFPA, the International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC) initiated the Global Psoriasis Atlas in 2015 and have continuously worked with the structure of the project, which was launched as a key milestone of the year in connection with World Psoriasis Day, October 29<sup>th</sup>. The upcoming Atlas launched was highlighted during the IFPA Members Meeting in July and showcased in connection with EADV 2019.

One of the key aims of the Global Psoriasis Atlas is to provide information about the worldwide epidemiology of psoriasis. Dermatologist and international organizations around the world will work together to update the GPA each year. The first edition contains data on the number of psoriasis cases in adults and children, healthcare data and personal stories told by people with psoriasis worldwide.

This is a key milestone from an epidemiological standpoint and IFPA would like to thank and acknowledge our partners, particularly the ILDS and IPC, and the Global Psoriasis Atlas team, for the extensive efforts that have gone into creating this important resource.

Further information is available on [www.globalpsoriasisatlas.org](http://www.globalpsoriasisatlas.org).

## Communications

IFPA's external and internal communications were further developed in 2019, focused on building connections within our network, and expanding our reach. Efforts were made to streamline the purpose and audience for each of our channels, and





consequently adding new tools and productions as needed. IFPA has continued efforts giving priority to rendering psoriasis and psoriatic arthritis visible on the global stage, spreading awareness not only of global advocacy, but also of regional and national initiatives to combat the unique challenges of psoriasis and psoriatic arthritis in every context.

Some highlights connected to communications efforts in 2019 include:

- Launched of an updated IFPA Quarterly Newsletter to keep our network updated on IFPA's projects, to raise global topics of interest related to psoriasis and psoriatic arthritis, and to highlight our members' impressive work at the regional and national levels.
- Expert social media coaching was offered to IFPA members as a part of a collaborative initiative.
- In conjunction with the new three-year strategy for World Psoriasis Day and the development of themes around messaging pillars, IFPA also created a new WPD social media strategy involving marketing ready-made messages to the public, and a detailed social media calendar.
- IFPA integrated new technical tools into our communications portfolio including in order to expand capacity to create varied resources, versatile social media posts, personalized animations, and smart schedules.

By end of 2019, IFPA had 14,817 Facebook followers, 5,247 Twitter followers, 818,400 Twitter impressions, and 636 followers on Instagram.

We were glad to get more connected and synergized with our members and partners on social media throughout the year, much in line with IFPA's updated strategy.

## The 6th IFPA World Psoriasis and Psoriatic Arthritis Conference in 2021

Following the successful implementation of the 5<sup>th</sup> World Psoriasis and Psoriatic Arthritis Conference in 2018, which included over 1,100 participants from around the world, IFPA began preparations in 2019 ahead of the next conference, which will take place in Stockholm in 2021. The theme of the next conference is *CONNECTED, INFORMED and UNITED to improve multidisciplinary care for people with psoriasis and psoriatic arthritis*.

Further information is available on [www.ifpaworldconference.com](http://www.ifpaworldconference.com).

## Corporate partners

IFPA substantially expanded collaborations with and support from corporate partners in 2019. Abbvie and Boehringer Ingelheim joined to support IFPA, as well as Janssen towards the end of the year.





As part of the IFPA Partnership Program, IFPA has received support in 2019 from Ammirall, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, LEO Pharma, Lilly, Novartis, Pfizer and UCB.

Support for the Global Psoriasis Coalition was provided by Abbvie, Ammirall, Bristol-Myers Squibb, Celgene, LEO Pharma, Novartis, and UCB.

For both categories, Janssen also joined in partnership with IFPA near end of year for further collaboration in 2020, including support for the Index project as listed below.

In 2019, Bristol-Myers Squibb, Celgene, LEO Pharma and Novartis provided support for the Psoriatic Disease Response Index project which continues in 2020.

Celgene and Novartis also jointly supported IFPA with particular funds in a joint capacity building project for IFPA members providing social media expertise, knowledge and toolkits, actioned in connection with the Members Meeting and continuing until World Psoriasis Day.

IFPA has also collaborated separately with numerous corporate partners in various projects and initiatives to provide additional value for people living with psoriasis and psoriatic arthritis.

IFPA would like to acknowledge and express our thanks for the important support received from our partners and the positive connections and synergies that provide value for the psoriasis community.

## Overall summary of progress in 2019

IFPA underwent significant expansion of operations and development of the organization in 2019. With a new and expanded Secretariat, updated work methodologies and a strategic multi-year approach, IFPA took new steps towards becoming more connected, informed and united. With the new Capacity Development Program in place, a focused global, regional and national connection strategy initiated, and extended sponsorships and partnerships, IFPA's capacity grew during the year, utilized during an intense operational year with extensive participation in key global conferences and events in the field, including the General Assembly. Together with our members, partners and supporters, IFPA is proud to have contributed to the health and well-being of people living with psoriasis and psoriatic arthritis worldwide through a number of key deliverables, including the launch of the Global Psoriasis Atlas, organization of a side event in connection with the United Nations High-Level Meeting on Universal Health Coverage, an extensive World Psoriasis Day campaign, and close collaborations in numerous projects and programs throughout the year.

IFPA's development was also highlighted as being among finalists in the International and European Association Awards in the category International Association of the Year.





INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

IFPA will continue growing and developing as a federation in line with our vision and mission. We thank all IFPA members, our partners and supporters, and stakeholders that make this possible together.

## Administration report

The Board of the International Federation of Psoriasis Associations hereby delivers the annual accounts for the year 2019-01-01 to 2019-12-31.

Regarding the result and financial positions, please refer to the attached statements.



**International Federation of Psoriasis Associations (IFPA)**  
**Org. no 802428-5986**

**Profit and loss account**

2019-01-01  
2019-12-31

2018-01-01  
2018-12-31

	SEK	EUR	SEK	EUR
<b>Incomes</b>		10,4336		10,2753
Membership fees	32426	3 108	58 516	5 695
Donations	0	0	0	0
Rounding- off to whole kronor	8	1	0	0
Amount WPC	0	0	3 735 890	363 580
Participation fees	0	0	0	0
Refunds and reimbursement	0	0	0	0
Boehringer-Ingelheim	349135	33 463	0	0
AbbVie	260 614	24 978	63 720	6 201
Almirall S.A	522 780	50 105	448 775	43 675
Sun Pharmaceutical Industries Inc.	0	0	0	0
LEO Pharma A/S	1 069 885	102 542	897 551	87 350
Bristol-Myers Squibb	1 172 182	112 347	675 305	65 721
UCB	1 050 600	100 694	670 209	65 225
Celgene	1 475 870	141 454	1 069 100	104 046
Novartis	1 536 514	147 266	979 536	95 329
Eli Lilly	736 792	70 617	897 551	87 350
Pfizer	751 394	72 017	614 114	59 766
Other operating income	0	0	0	0
<b>Total income</b>	<b>8 958 199</b>	<b>858 591</b>	<b>10 110 264</b>	<b>983 939</b>

## Profit and loss account

2019-01-01  
2019-12-31

2018-01-01  
2018-12-31

	SEK	EUR	SEK	EUR
<b>Costs</b>		10,4336		10,2753
Outgoing donations	0	0	-94 479	-9 195
Office rental agreement	-560 693	-53 739	-396 841	-38 621
Freight and transport	-756	-72	-6 952	-677
Conference costs	-1 476 405	-141 505	-71 301	-6 939
Tele meetings	-2 000	-192	-9 313	-906
Travel costs	-331 200	-31 744	-449 011	-43 698
Refund members	-69 349	-6 647	-202 620	-19 719
Hotel costs	-368 262	-35 296	-236 662	-23 032
Food	-63 976	-6 132	-41 393	-4 028
Reimbursement	-610 396	-58 503	-250 852	-24 413
Printing costs	-57 656	-5 526	-86 797	-8 447
PR-Marketing	-287 599	-27 565	-122 692	-11 940
Entertainment	-19 545	-1 873	-36 179	-3 521
Gifts	-8 400	-805	-9 191	-895
Office material	-124 095	-11 894	-165 955	-16 151
Phone	-65 234	-6 252	-36 864	-3 588
Insurance for the organization	-11 453	-1 098	-7 772	-756
Losses on receivables	0	0	0	0
Accountant and audit	-241 142	-23 112	-214 602	-20 885
Consultants	-2 547 952	-244 206	-1 964 221	-191 159
Web	-31 367	-3 006	-2 787	-271
News service	-28 935	-2 773	-49 500	-4 817
Bank fees	-8 805	-844	-9 616	-936
Wire transaction fees	0	0	-376	-37
Membership fees	-243 548	-23 343	-198 542	-19 322
Subscriptions and articles	-93 125	-8 925	-7 580	-738
Other operating expenses	66 370	6 361	-284 592	-27 697
Interest taxes and fees	-1 130	-108	-469	-46
Staff costs	-4 068 248	-389 918	-2 458 450	-239 258
Exchange profit/loss	-147 804	-14 166	95 592	9 303
<b>Total costs</b>	<b>-11 402 705</b>	<b>-1 092 883</b>	<b>-7 320 017</b>	<b>-712 390</b>
<b>Profit (+) / Loss (-)</b>	<b>-2 444 505</b>	<b>-234 292</b>	<b>2 790 247</b>	<b>271 549</b>

## Costs per activity

2019-01-01  
2019-12-31

2018-01-01  
2018-12-31

	SEK	EUR 10,4336	SEK	EUR 10,2753
<b>1. WPC</b>				
Freight and transport	0	0	-3 791	-369
Conference costs	0	0	0	0
Travel costs	-5 404	-518	-3 469	-338
Hotel costs	0	0	0	0
Food	-40	-4	-4 920	-479
Reimbursement	0	0	-15 433	-1 502
Printing costs	0	0	-23 913	-2 327
PR-Marketing	0	0	-114 190	-11 113
Gifts	0	0	-2 860	-278
Office material	0	0	-780	-76
Consultants	-60 927	-5 839	-88 674	-8 630
Other operating expenses	66 370	6 361	-284 592	-27 697
Exchange profit/ loss	0	0	-5 710	-556
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-548 330</b>	<b>-53 364</b>

<b>2. World Psoriasis Day</b>				
Freight and transport	0	0	0	0
Conference costs	-1 277 809	-122 471	0	0
Travel costs	-23 517	-2 254	-27 399	-2 666
Refund members	-20 114	-1 928	-199 529	-19 418
Hotel costs	0	0	0	0
Food	-729	-70	-509	-49
Reimbursement	-238 590	-22 867	-58 902	-5 732
Printing costs	-21 894	-2 098	-7 088	-690
PR-Marketing	-10 573	-1 013	-8 502	-827
Office material	-6 838	-655	0	0
Consultants	-680 383	-65 211	0	0
Web	-21 042	-2 017	-1 203	-117
Newsservice	-111	-11	0	0
Bank fee	-107	-10	0	0
Subscriptions and articles	-406	-39	0	0
Exchange profit/ loss	-6 222	-596	-954	-93
<b>Total costs</b>	<b>- 2 308 335</b>	<b>-221 240</b>	<b>-304 084</b>	<b>-29 594</b>

## Costs per activity

	2019-01-01 2019-12-31		2018-01-01 2018-12-31	
	SEK	EUR 10,4336	SEK	EUR 10,2753
<b>4. EADV</b>				
Conference costs	-19 964	-1 913	-24 006	-2 336
Travel costs	-49 550	-4 749	-29 053	-2 827
Hotel costs	-42 737	-4 096	-43 585	-4 242
Food	-6 405	-614	-8 018	-780
Reimbursement	-77 522	-7 430	-18 544	-1 805
Print costs information material	-406	-39	0	0
PR Marketing	-900	-86	0	0
Exchange profit/ loss	-0	0	-2 488	-242
<b>Total costs</b>	<b>-197 484</b>	<b>-18 928</b>	<b>-125 693</b>	<b>-12 233</b>
<b>5. External Meetings</b>				
Conference costs	0	0	-18 397	-1 790
Travel costs	0	0	-33 617	-3 272
Hotel costs	0	0	-24 292	-2 364
Food	0	0	0	0
Reimbursement	-15 879	-1 522	-5 197	-506
Wire transaction fees	0	0	-125	-12
<b>Total costs</b>	<b>-15 879</b>	<b>-1 522</b>	<b>-81 627</b>	<b>-7 944</b>
<b>6. EC Meetings</b>				
Conference costs	-38 333	-3 674	-17 480	-1 701
Travel costs	0	0	-170 712	-16 614
Hotel costs	0	0	-112 392	-10 938
Food	0	0	-15 821	-1 540
Reimbursement	-24 032	-2 303	-23 232	-2 261
Wire transaction fees	0	0	-252	-24
<b>Total costs</b>	<b>-62 365</b>	<b>-5 977</b>	<b>-339 888</b>	<b>-33 078</b>
<b>7. Psoriasis Atlas</b>				
Print costs information material	0	0	-2 731	-266
Web	0	0	-129	-13
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-2 860</b>	<b>-278</b>

## Costs per activity

2019-01-01  
2019-12-31

2018-01-01  
2018-12-31

	SEK	EUR 10,4336	SEK	EUR 10,2753
<b>8. Advocacy</b>				
Freight and transport	0	0	-731	-71
Travel costs	-33 996	-3 528	-56 890	-5 537
Hotel costs	-52 354	-5 018	-17 444	-1 698
Food	-6 192	-593	-3 693	-359
Reimbursement	-62 507	-5 991	-13 792	-1 342
Print costs information material	-4 856	-465	0	0
PR marketing	-274 126	-26 273	0	0
Entertainment	-19 436	-1 863	-31 628	-3 078
Bank fee	-91	-9	0	0
Membership fees	-241 090	-23 107	0	0
Exchange profit/ loss	-3 574	-343	-1 204	-117
<b>Total costs</b>	<b>-698 222</b>	<b>-66 921</b>	<b>-125 382</b>	<b>-12 131</b>

<b>10. IFPA</b>				
Office rental agreement	-560 693	-53 739	-396 840	-38 621
Freight and transport	-756	-72	-1 477	-144
Conference costs	-110 308	-10 572	0	0
Tele meetings	-2 000	-192	-8 650	-842
Travel costs	-218 734	-20 964	-53 869	-5 243
Refund members	-49 235	-4 719	0	0
Hotel costs	-273 170	-26 182	-11 738	-1 142
Food	-50 610	-4 851	-8 432	-821
Reimbursement	-180 296	-17 280	-67 473	-6 567
Printing costs	-13 831	-1 326	-43 715	-4 254
PR-Marketing	-2 000	-192	0	0
Entertainment	-109	-10	-4 551	-443
Gifts	-8 400	-805	-6 331	-616
Office material	-117 258	-11 238	-165 175	-16 075
Phone	-65 234	-6 252	-36 864	-3 588
Insurance for the organisation	-11 453	-1 098	-7 772	-756
Accountant and audit	-241 142	-23 112	-214 602	-20 885
Consultants	-325 212	-31 170	-511 931	-49 822

## Costs per activity

	2019-01-01 2019-12-31		2018-01-01 2018-12-31	
	SEK	EUR	SEK	EUR
<b>10. IFPA</b>		10,4336		10,2753
Web	-10 326	-990	-1 455	-142
News service	-28 875	-2 768	-49 500	-4 817
Bank fees	-8 608	-825	-9 616	-936
Membership fees	-2 457	-236	-2 457	-239
Subscription and articles	-92 719	-8 887	0	0
Salary costs	-4 068 248	-389 918	0	0
Losses on receivables	0	0	0	0
Interest expenses for taxes and fees	-1 079	-103	0	0
Exchange profit/loss	-78 436	-7 518	-7 580	-738
	<b>-6 521 189</b>	<b>-625 018</b>	<b>-3 973 085</b>	<b>-386 664</b>

<b>12. IFPA Solidarity Fund</b>				
Outgoing donations	0	0	0	0
Refund members	0	0	-3 091	-301
<b>Total costs</b>	<b>0</b>	<b>0</b>	<b>-3 091</b>	<b>-301</b>

<b>13. Global Psoriasis Coalition</b>				
Outgoing donations	0	0	-94 479	-9 195
Freight and transport	0	0	-954	-93
Conference costs	-29 991	-2 874	-11 419	-1 111
Tele meetings	0	0	-663	-65
Travel costs	0	0	-74 003	-7 202
Hotel costs	0	0	-27 211	-2 648
Food	0	0	0	0
Reimbursement	-11 569	-1 109	-48 279	-4 699
Printing costs	-16 669	-1 598	-9 350	-910
PR-Marketing	0	0	0	0
Office material	0	0	0	0
Consultants	-992 844	-95 158	-1 363 616	-132 708
Bank fees	0	0	0	0
Wire transaction fees	0	0	0	0
Membership fees	0	0	-196 085	-19 083
Exchange profit/loss	-47 509	-4 553	10 083	981
<b>Total costs</b>	<b>-1 098 581</b>	<b>-105 293</b>	<b>-1 815 976</b>	<b>-176 732</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

## Costs per activity

	2019-01-01 2019-12-31		2018-01-01 2018-12-31	
<b>15. Psoriasis Readiness Index</b>				
Consultants	-488 586	-46 828	0	0
Exchange profit/loss	-12 063	-1 156	0	0
<b>Total costs</b>	<b>-500 649</b>	<b>-47 984</b>	<b>0</b>	<b>0</b>

These cost centers didn't have any costs year 2019 and 2018:

### 09. Under the spotlight



## Balance sheet

		2019-01-01 2019-12-31		2018-01-01 2018-12-31	
	Note	SEK	EUR	SEK	EUR
<b>Bank assets and claims</b>			10,4336		10,2753
Outstanding claims	1	2 472 203	236 946	5 385 634	524 134
Other claims		2	0	202	20
Prepaid expenses and accrued income	2	294 930	28 267	198 301	19 299
Cash		2 153	206	2 308	225
Bank Nordea		8 128 397	779 060	3 876 328	377 247
<b>Total bank assets and claims</b>		<b>10 897 684</b>	<b>1 044 480</b>	<b>9 462 774</b>	<b>920 924</b>

		2019-01-01 2019-12-31		2018-01-01 2018-12-31	
	Note	SEK	EUR	SEK	EUR
<b>Capitals and creditors</b>			10,4336		10,2753
Capital		8 527 827	817 343	5 737 580	558 386
Profit or loss		-2 444 505	-234 292	2 790 247	271 549
Outstanding debts		1 286 059	123 261	164 125	15 973
Other debts		864 645	82 871	647 055	62 972
Prepaid income	3	1 997 723	191 470	212	21
Accrued expenses and fee paid in advance	4	665 934	63 826	123 554	12 024
<b>Total capital and creditors</b>		<b>10 897 684</b>	<b>1 044 480</b>	<b>9 462 774</b>	<b>920 924</b>

## Notes

2019-01-01  
2019-12-31

2018-01-01  
2018-12-31

	SEK	EUR	SEK	EUR
		10,4336		10,2753

### Note 1 Outstanding claims

Pfizer Inc.	751 394	72 017	0	0
UCB	1 720 809	164 930	670 209	65 225
MeetAgain Konferens AB	0	0	3 735 890	363 580
Novartis Pharma AG	0	0	979 536	95 329
Israel Psoriasis Association	0	0	0	0
<b>Total</b>	<b>2 472 203</b>	<b>236 946</b>	<b>5 385 634</b>	<b>524 134</b>

### Note 2 Prepaid expenses and accrued income

Alviks Strand kontorshotell	131 530	12 606	105 637	10 281
Arén & Partner	862	83	862	84
International Alliance of Patients of Psoriasis	2 457	236	4 915	478
Fortnox AB	1 865	179	1 845	180
Europeiska ERV	7 500	719	7 143	695
Newsmachine Business Intelligence NMBI AB	20 625	1 977	0	0
Prepaid rental expenses	0	0	14 180	1 380
Accrued income Abbvie	63 720	6 107	63 720	6 201
Prepaid cost WPC	66 370	6 361	0	0
<b>Total</b>	<b>294 930</b>	<b>28 267</b>	<b>198 301</b>	<b>19 299</b>

### Note 3 Prepaid income

Abbvie	260 614	24 978	0	0
Bristol Myers Squibb	1 199 182	114 935	0	0
Boehringer Ingelheim International GmbH	349 135	33 463	0	0
Celgene	97 333	9 329	0	0
Novartis	91 460	8 766	0	0
Psoriasis Association of Kenya	0	0	212	21
<b>Total</b>	<b>1 997 723</b>	<b>191 470</b>	<b>212</b>	<b>21</b>



INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

#### Note 4 Accrued costs and fees paid in advance

Hummelkläppen	60 000	5 751	30 000	2 920
Accrued expenses Patrik Vuorio 2018 & 2019	221 514	21 231	75 918	7 388
Accrued reimbursement Turkey 2018	2 636	253	2 636	257
Accrued cost BBC	274 126	26 273	0	0
Accrued reimbursement Hoseah Waweru 2019	39 013	3 739	15 000	1 460
Accrued reimbursement Puerto Rico AAD 2019	9 913	950	0	0
Accrued reimbursement David Trigos 2019	9 497	910	0	0
Accrued reimbursement Israel 2019	6 458	619	0	0
Accrued reimbursement Kenya 2019	10 433	1 000	0	0
Accrued reimbursement USA 2019	10 433	1 000	0	0
Accrued reimbursement Global Skin 2019	10 433	1 000	0	0
Accrued reimbursement Panama 2019	11 477	1 100	0	0
<b>Total</b>	<b>665 934</b>	<b>63 826</b>	<b>123 554</b>	<b>12 024</b>





INTERNATIONAL FEDERATION  
OF PSORIASIS ASSOCIATIONS

Date of signing: 2020-12-17

Hoseah Waweru  
President

Ingvar Ingvarsson  
Vice President

Leticia Lopez  
Secretary

Josef de Guzman  
Treasurer

Silvia Fernandez Barrio  
Acting Member-at-Large (Substitute for Kathleen Gallant)

Tommy Nilsson  
Authorized Public Accountant



# Verification

Transaction 09222115557439338943

## Document

Annual Accounts 2019\_updated 201216

Main document

24 pages

Initiated on 2020-12-17 15:42:33 CET (+0100) by Ida Mourujärvi (IM)

Finalised on 2020-12-23 10:37:45 CET (+0100)

## Initiator

Ida Mourujärvi (IM)

IFPA International Federation of Psoriasis Associations

ida.mourujarvi@ifpa-pso.com

0736635251

## Signing parties

Hoseah Waweru (HW)

IFPA

hoseah.waweru@ifpa-pso.com



Signed 2020-12-17 20:25:41 CET (+0100)

Ingvar Ágúst Ingvarsson (IÁI)

IFPA

ingvar.ingvarsson@ifpa-pso.com



Signed 2020-12-22 09:19:59 CET (+0100)

Leticia Lopez (LL)

IFPA

leticia.lopez@ifpa-pso.com



Signed 2020-12-18 12:50:49 CET (+0100)

Josef de Guzman (JdG)

IFPA

josef.deguzman@ifpa-pso.com



Signed 2020-12-17 15:51:10 CET (+0100)

Silvia Fernandez Barrio (SFB)

IFPA

silviafb@ifpa-pso.com



Signed 2020-12-17 15:47:16 CET (+0100)

Tommy Nilsson (TN)

Hummelkläppen

tommy.nilsson@hummelklappen.se



Signed 2020-12-23 10:37:45 CET (+0100)



# Verification

Transaction 09222115557439338943

This verification was issued by Scrive. Information in italics has been safely verified by Scrive. For more information/evidence about this document see the concealed attachments. Use a PDF-reader such as Adobe Reader that can show concealed attachments to view the attachments. Please observe that if the document is printed, the integrity of such printed copy cannot be verified as per the below and that a basic print-out lacks the contents of the concealed attachments. The digital signature (electronic seal) ensures that the integrity of this document, including the concealed attachments, can be proven mathematically and independently of Scrive. For your convenience Scrive also provides a service that enables you to automatically verify the document's integrity at: <https://scrive.com/verify>





## Translation of Auditor's Report

### To the meeting of the General Assembly of its Full members of International Federation of Psoriasis Associations

Corporate identity number 802428-5986

### Report on the annual accounts

#### *Opinions*

I have audited the annual accounts of International Federation of Psoriasis Associations for the financial year 2019.

In my opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of International Federation of Psoriasis Associations as of 31 december 2019 and its financial performance for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts.

I therefore recommend that the general meeting of members adopts the income statement and balance sheet.

#### *Basis for Opinions*

I conducted my audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

#### *Responsibilities of the Board of Directors*

The Board of Directors is responsible for the preparation of the annual accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors is also responsible for such internal control as it determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, The Board of Directors is responsible for the assessment of the company's ability to continue as a going concern. It discloses, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is not applied if decision has been taken to discontinue the operations.

#### *Auditor's responsibility*

My objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts.

As part of an audit in accordance with ISAs, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the annual accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of the company's internal control relevant to my audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors .

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting in preparing the annual accounts. I also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify my opinion about the annual accounts. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts, including the disclosures, and whether the annual accounts represent the underlying transactions and events in a manner that achieves fair presentation.

I must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. I must also inform of significant audit findings during my audit, including any significant deficiencies in internal control that I identified.

## **Report on other legal and regulatory requirements**

### ***Opinions***

In addition to my audit of the annual accounts, I have also audited the administration of the Board of Directors of International Federation of Psoriasis Associations for the financial year 2019 and the proposed appropriations of the company's profit or loss.

I recommend to the general meeting of members that the loss be dealt with in accordance with the proposal in the statutory administration report and that the of the Board of Directors be discharged from liability for the financial year.

### ***Basis for Opinions***

I conducted the audit in accordance with generally accepted auditing standards in Sweden. My responsibilities under those standards are further described in the *Auditor's Responsibilities* section. I am independent of International Federation of Psoriasis Associations in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled my ethical responsibilities in accordance with these requirements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinions.

### ***Responsibilities of the Board of Directors***

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's type of operations, size and risks place on the size of the company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner.



***Auditor's responsibility***

My objective concerning the audit of the administration, and thereby my opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors in any material respect:


- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

My objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby my opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, I exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on my professional judgment with starting point in risk and materiality. This means that I focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. I examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to my opinion concerning discharge from liability. As a basis for my opinion on the Board of Directors' proposed appropriations of the company's profit or loss I examined whether the proposal is in accordance with the Companies Act.

Stockholm 2020-12-23

  
Tommy Nilsson  
Authorized Public Accountant